AstraZeneca’s China business under spotlight amid fraud case

AstraZeneca's ( NASDAQ: AZN ) selloff on Tuesday in response to reports that the company is facing a fraud investigation in China highlights how much value the Anglo-Swedish pharma giant has attached to the country, the company's third largest market. The widening investigation.